Summary
Possible cAMP-dependent and cAMP-independent mechanisms of action for the cardiac effects of OPC-8212, a novel piperazinyl-quinolinone derivative, were evaluated. OPC-8212 was tested for in vitro potency as an inhibitor of soluble bovine cardiac phosphodiesterases using a rapid isolation and assay method involving monoclonal antibodies that distinguish among isozymes. The drug was selective for a low-K m, cGMP-inhibited phosphodiesterase (CGI-PDE) with an IC50 (half-maximal inhibition concentration) of 7.4 μmol/l when measured at a substrate level of 0.35 μmol/l cAMP. Under the conditions used, sulfolane, the solvent for OPC-8212, did not affect CGI-PDE activity. In electrophysiological measurements, OPC-8212 prolonged the action potential duration in canine Purkinje strand preparations up to 148% (APD90) at 10 μmol/l. Concomitantly, OPC-8212 produced a 100% increase in developed force. Both prolongation of the action potential duration and the positive inotropic effect were readily reversed after exposure to tetrodotoxin, 3 μmol/l. Using Na-selective microelectrodes, intracellular Na+ ion activity increased 225% upon exposure to 10 μmol/l OPC-8212. OPC-8212 represents a novel type of positive inotropic agent, possessing both cAMP-dependent (selective PDE isozyme inhibition) and cAMP-independent (activation of intracellular Na+) mechanism of action.
Similar content being viewed by others
References
Beavo JA, Hansen RS, Harrison SA, Hurwitz RL, Martins J, Mumby MD (1983) Identification and properties of cyclic nucleotide phosphodiesterases. Mol Cell Endocrinol 28:387–410
Berger C, Meyer W, Scholz H, Starbatty J (1985) Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxyphenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl)benzimidazole-HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts. Arzneimittelforsch/Drug Res 35:1668–1673
Buggisch D, Isenberg G, Ravens U, Scholtysik G (1985) The role of sodium channels in the effects of the cardiotonic compound DPI 201–106 on contractility and membrane potentials in isolated mammalian heart preparations. Eur J Pharmacol 118:303–311
Dage RC, Roebel LE, Hsieh CP, Weiner DL, Woodward JK (1982) Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1,3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). J Cardiovasc Pharmacol 4:500–508
Dorn WS, McCracken DD (1972) In: Numerical methods with FORTRAN-IV case studies. John Wiley & Sons, New York, NY, USA, pp 155–175; pp 324–330
Eisner DA, Lederer WJ, Sheu S-S (1983) The role of intracellular sodium activity in the anti-arrhythmic action of local anaesthetics in sheep Purkinje fibres. J Physiol (Lond) 340:239–257
Endo M (1984) The effect of a new positive inotropic agent, 3,4dihydro-6-[4-(3,4-dimethoxybenzoyl)-7-piperazinyl]-2-(1 H)quinolinone (OPC-8212), on thin bundles of skinned fibres from cardiac muscle. Arzneimittelforsch/Drug Res 34:380–383
Fozzard HA, Wasserstrom JA (1985) Voltage dependence of intracellular sodium and control of contraction. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology and arrhythmias. Grune and Stratton, Orlando, FL, USA, pp 51–57
Grupp G, Grupp IL, Newman G, Schwartz A (1984) Effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1 H)-quinolinone (OPC-8212) and its solvent sulfolane on isolated heart preparations of the rat, guinea pig and dog. Arzneimittelforsch/Drug Res 34:359–363
Grupp G, Grupp IL, Kojima M, Sperelakis N, Tsuchiya Y, Hosakawa T, Schwartz A (1986) Hemodynamic and electrophysiological effects of a novel positive inotropic drug, OPC8212, in normal and “failing” guinea pig heart preparations. J Cardiovasc Pharmacol 8:428–440
Güggi M, Oehme M, Pretsch E, Simon W (1976) Neutraler Inophor für Flüssigmembranelektroden mit holier Selektivität für Natrium-gegenüber Kalium-Ionen. Helvetica Chimica Acta 59:2417–2420
Hansen RS, Beavo JA (1982) Purification of two calcium/calmodulin dependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatography. Proc Natl Acad Sci USA 79:2788–2792
Harned HS, Robinson RA (1968) In: Multicomponent electrolytes solutions. Paragon Press, Oxford
Harrison SA, Chang ML, Beavo JA (1986a) Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs. Circ 73 (Suppl. III):109–116
Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA (1986b) Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29:506–514
Honerjäger P (1982) Cardioactive substances that prolong the open state of sodium channels. Rev Physiol Biochem Pharmacol 92:1–74
Honerjäger P, Heiss A, Schäfer-Korting M, Schönsteiner G, Reiter M (1984) UD-CG 115—a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea pig papillary muscle. Naunyn-Schmiedeberg's Arch Pharmacol 325:259–269
Honerjäger P, Loibl E, Steidl I, Schönsteiner G, Ulm K (1986) Negative inotropic effects of tetrodotoxin and seven class I antiarrhythmic drugs in relation to sodium channel blockade. Naunyn-Schmiedeberg's Arch Pharmacol 332:184–194
Horackova M, Vassort G (1973) Ionic mechanism of inotropic effect of veratrine on frog heart. Pflügers Arch 341:281–284
Hosakawa T, Grupp IL, Grupp G, Lathrop D, Matlib M, Wang T, Lee SW, Schwartz A (1984) Studies on the mechanism of OPC-8212, a new positive inotropic agent. Fed Proc (Abstract) 43:937
Iijima T, Taira N (1987) Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 240:657–662
Kaufmann RF, Crowe VG, Utterback BG, Robertson DW (1986) LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol 30:609–616
Kitada Y, Narimatsu A, Matsumura N, Endo M (1987) Increase in Ca++ sensitivity of the contractile system by MCI-154, a novel cardiotonic agent, in chemically skinned fibres from the guinea pig papillary muscles. J Pharmacol Exp Ther 243:644–648
Kohlhardt M, Fröbe U, Herzig JW (1987) Removal of inactivation and blockade of cardiac Na+ channels by DPI 201–106: different voltage-dependencies of the drug actions. Naunyn-Schmiedeberg's Arch Pharmacol 336:183–188
Lathrop DA, Schwartz A (1984) Electro-mechanical effects of 3,4dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a new positive inotropic agent. Arzneimittelforsch/Drug Res 34:371–375
Lathrop DA, Schwartz A (1985) Evidence for possible increase in sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OPC-8212. Eur J Pharmacol 117:391–392
Martins TJ, Mumby MC, Beavo JA (1982) Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem257:1973–1979
Morad M, Trautwein W (1968) The effect of the duration of the action potential on contraction in the mammalian heart muscle. Pflügers Arch 299:66–82
Müller-Beckmann B, Freund P, Honerjäger P, Kling L, Rüegg JC (1988) In vitro investigations on a new positive inotropic and vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J Cardiovasc Pharmacol 11:8–16
Rapundalo ST, Grupp IL, Grupp G, Matlib MA, Solaro RJ, Schwartz A (1986) Myocardial actions of milrinone: characterization of its mechanisms of action. Circ 73 (Suppl. III):134–144
Rüegg JC (1986) Effects of new inotropic agents on C2+ sensitivity of contractile proteins. Circ 73 (Suppl. III):78–84
Satoh H, Hashimoto K (1984) Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC8212) on the membrane currents of rabbit sino-atrial node cells. Arzneimittelforsch/Drug Res 34:376–380
Scholtysik G, Salzmann R, Berthold R, Herzig JW, Quasi U, Markstein R (1985) DPI 201–106, a novel cardiotonic agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilating properties. Naunyn-Schmiedeberg's Arch Pharmacol 329:316–325
Scholz H (1980) Effects of beta- and alpha-adreno-receptor activators and adrenergic transmitter releasing agents on the mechanical activity of the heart. In: Szekeres L (ed) Handbook of experimental pharmacology, vol 54/I: Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 651–733
Scholz H (1983) Pharmacological actions of various inotropic agents. Eur Heart J 4 (Suppl. A):161–172
Schwartz A, Wallick ET, Lee SW, Wang T, Hosakawa T, Whitmer KR, Matlib MA (1984) Studies on the mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)quinolinone (OPC-8212), a new positive inotropic drug. Arzneimittelforsch/Drug Res 34:384–389
Shen S-S, Fozzard HA (1982) Transmembrane Na+ and Ca2+ electromechanical gradients in cardiac muscle and their relationship to force development. J Gen Physiol 80:325–351
Sokal RR, Rohlf FJ (1969) Biometry. Freeman, San Francisco, CA, USA, pp 126–140
Taira N, Endoh M, Iijima T, Satoh K, Yanagisawa T, Yamashita S, Maruyama M, Kawada M, Morita T, Wada Y (1984) Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart. Arzneimittelforsch/Drug Res 34:347–355
Thompson WJ, Teresaki WL, Epstein PM, Strada SJ (1979) Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyc Nuc Res 10:69–92
Tsien R (1973) Adrenaline-like effects of intracellular iontophoresis of cyclic AMP in cardiac Purkinje fibres. Nature 245:120–122
Weishaar R, Kobylarz-Singer DC, Steffen RP, Kaplan HR (1987) Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 61:539–547
Yamashita S, Hosakawa T, Kojima M, Mori T, Yabuuchi Y (1984) In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC 8212), a novel positive inotropic drug, in various animals. Arzneimittelforsch/Drug Res 34:342–346
Yanagisawa T, Endoh M, Taira N (1984) Involvement of cyclic AMP in the positive inotropic effect of OPC-8212, a new cardiotonic agent, on the canine ventricular muscle. Jpn J Pharmacol 36:379–388
Author information
Authors and Affiliations
Additional information
Send offprint requests to A. Schwartz at the above address
Rights and permissions
About this article
Cite this article
Rapundalo, S.T., Lathrop, D.A., Harrison, S.A. et al. Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212. Naunyn-Schmiedeberg's Arch Pharmacol 338, 692–698 (1988). https://doi.org/10.1007/BF00165636
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00165636